Thank you!
Your support is sustaining the future of local news in our communities.

Omicron, surely that’s enough

What have the scientific, pharmaceutical, and medical communities done to stifle SARS-CoV-2 infections? There are currently 18 advanced trials of different vaccines, 64 possible new treatments, and 23 potential or approved anti-viral drugs.

The mRNA vaccines from Pfizer and Moderna provide robust protection. (The mRNA technology is being expanded to HIV, malaria, and other diseases for which conventional vaccines have failed.) mRNA vaccines are expensive and need to be shipped frozen. Lower income countries require an effective vaccine that is inexpensive, survives at higher temperature and can be made locally.  Corbevax, created at Baylor College of Medicine, fits these criteria and is currently being made in hundreds of millions of doses in India. Other vaccines (Novovax) produce antibodies to viral proteins in addition to the Spike protein. The Novovax vaccine contains no genetic material.

Beyond vaccines there are 64 new treatments in development that block or slow infection or some of its consequences, like inflammation. Inflammation makes blood vessels leaky; defensive cells, which rush to the site of infection, squeeze out of the circulation, and infiltrate the lungs. They fill air sacs with dead neutrophils, eosinophils, and fluid, making the patient struggle to breathe.  In addition to the inflammatory reaction, when these cells die they release digestive enzymes that can do terrible damage to the lungs or other infected tissues. The use of steroids to inhibit inflammation was a critical early discovery. According to a review I read recently, it is still the best early intervention. Most viruses have means to inhibit a host’s immune system:  some inhibit interferon synthesis, a critical mobilizer of the immune response; SARS-CoV-2 inhibits the production of Natural Killer cells, which recognize infected lung cells and kill them. The more we know about these mechanisms the better off we will be.

There are currently 23 antivirals approved or in testing, including Merck’s Molnupiravir and Pfizer’s Paxlovid, but others have Emergency Use Authorizations as well. Paxlovid, if taken within 5 days of the onset of symptoms, blocks disease progression and keeps 90% of patients from hospitalization.  As a result, our hospitals are able to function, saving money, reducing misery and increasing morale.  Vaccinated and boosted people usually have a short illness unless they have other complications and may not need these therapeutics. But for those who do, or are unvaccinated the drugs are becoming available in pharmacies.

My friend, Jonathan Sanoff, keeps track of these things. He told me about a site called the Therapeutics Locator, which The Assistant Secretary for Preparedness and Response at The Department of Health and Human Services and her staff have prepared. The Assistant Secretary is Rear Admiral Rachel L. Levine, MD. The site tells potential patients where to find these drugs, whether they are in Puerto Rico or Alaska. For skeptics, the site also includes the number of doses on hand at each site and the total made so far, as well as information on each drug. As new therapies come online, they will appear on the Therapeutics Locator. There are currently seven drugs and monoclonal antibodies on the site. The Asst Secretary and her staff do not get much credit, but they should. See: www.covid-19-therapeutics-locator-dhhs.hub.arcgis.com/.

It is important to have many anti-viral drugs, and I was surprised to learn that 23 are still in late clinicals trials. We learned from HIV therapy that an RNA virus can develop resistance to a single drug but cannot evolve resistance to three drugs and is why the number 23 is a pleasant surprise. An even better surprise is, some of these drugs inhibit other RNA viruses, including Zika and Ebola.

Nothing in science or medicine must work, no matter how clever the idea. We should not be surprised that 26 vaccines failed, 92 treatments did not pass muster, and 54 antivirals did not inhibit SARS-CoV-2.  These results on therapies in the development pipeline have been collected by Heidi Ledford, one of Nature Magazine’s senior reporters (Nature, March 3, 2022). I am grateful to her. In that context, the March 11 issue of Science, the flagship publication of the American Academy of Sciences, contains a detailed comparison and analysis of these treatments and ideas on what we need to prepare for the next epidemic. Pandemics are too large a subject to cover everything — we have left out the value of logistics and convincing people to take vaccines, not to mention long Covid, but people are studying these challenges. The combination of basic science, private industry, and public health services have done well, although praise sounds hollow when millions have died.

What to do? Get vaccinated and boosted. When new boosters designed to attack SARS-CoV-2 or its variants appear, get those too. Even with the vaccine, you may get mild disease, but the name of the game is to prevent progress to serious disease and hospitalization. The new drugs offer reassurance. In places where the virus and infection are in decline, it is time to resume normal life.  Or at least that is my plan.

 

Richard Kessin is Emeritus Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center. Reach him at Richard.Kessin@gmail.com. His website contains more information: RichardKessin.com.

 

 

       

             

 

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

Berkshire League boys tennis takes shape, sets championships for May 26

Gustavo Portillo of HVRHS volleys during the opening rounds of the postseason tournament

Riley Klein

LAKEVILLE – Berkshire League boys tennis players gathered at The Hotchkiss School Tuesday, May 19, for the opening rounds of the postseason tournament.

The event featured three separate brackets: varsity singles, varsity doubles and junior varsity doubles. Matches began early in the morning and continued until about 2 p.m. with the temperature cranked up to 90 degrees.

Keep ReadingShow less
Plans to revitalize Norfolk’s Infinity Hall unveiled

Infinity Hall, built in 1883.

Jennifer Almquist

Nearly 200 people packed the wooden seats of Norfolk’s historic Infinity Hall on Thursday, May 14, as David Rosenfeld, owner and founder of Goodworks Entertainment Group, a live entertainment and venue management company, unveiled ambitious plans to restore the restaurant and bar, expand programming and reestablish the venue as a central gathering place for the community.

Since the Norfolk Pub closed on Jan. 31, 2026, the need for a restaurant and evening gathering place has become paramount, and for years residents have wanted Infinity Hall to be more engaged with the community.

Keep ReadingShow less

May Castleberry’s next chapter

May Castleberry’s next chapter

May Castleberry at home in Lakeville.

Natalia Zukerman
Castleberry’s idea of happiness is “looking at a great painting.”

May Castleberry is a ball of sunshine and passion, though she grew up an introverted child, moving with her family from Alberta to Colorado to Texas, finding comfort in mountains, books and wide-open skies. Today, the former art book editor and museum curator has found a new home in Lakeville, where the natural beauty of the Northwest Corner continues to captivate her. Whether walking with friends, painting, reading or visiting beloved local libraries in Salisbury, Norfolk and Cornwall, Castleberry has embraced the region since making her move permanent in 2022, bringing with her a remarkable career shaped by a lifelong love of books and art.

Castleberry grew up in the world of books, and especially art books, and she credits her artist mother, an avid art book collector, with igniting her passions. Castleberry’s high school art teacher in Dallas understood how to teach students to channel their imaginations into books and art.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Hoarding 
With Style: Sarah Blodgett’s art of collecting

Sarah Blodgett has turned her passion for collecting into “something larger.”

Photo by Sarah Blodgett

There is something wonderfully disarming about walking into a space where nothing feels overly polished, overly planned or pulled from a catalog — a place where history lingers in the corners, where color is fearless, where the objects on the shelves have stories to tell and where, if you are lucky, a cat named Cinnamon may be supervising the entire operation.

That is the world of Sarah Blodgett.

Keep ReadingShow less

Dr. Paul J. Fasano

Dr. Paul J. Fasano

SHARON — Dr. Paul J. Fasano DDS, of Brewster, Massachusetts, passed away peacefully after a long illness on May 10, 2026, in Boston.

Born in Boston to Philip and Laura (Stolarsky) Fasano on Dec. 13, 1946, he grew up in Dorchester with his two brothers Philip and William.Paul attended the Boston Latin School and graduated from Boston College in 1968.He later completed Dental School at New York University in 1972.

Keep ReadingShow less

David Niles Parker

David Niles Parker

KENT — David Niles Parker, 88, of Middletown, Connecticut, passed away at home on May 6, 2026.

Born January 20, 1938, in Wellesley, Massachusetts, the first child to Franklin and Katharine Niles Parker, David graduated from Wellesley High School, received his undergraduate degree from Wesleyan University, studied at the University of Chicago Divinity School, and earned his master’s in education from Harvard.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.